Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Media
About Us
Our Stories
Join Us
Contact Us
简
EN
繁
Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Media
About Us
Our Stories
Join Us
Contact Us
简
EN
繁
Please enter the information you want to find
Hot key words:
Hyaluronidase
xxx
News Center
All
2025.12.10
Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics
View details
2025.12.12
Exploring the Frontiers of Clinical Innovation: Bao Pharma Participating in the National Xenotransplantation Mega-Project
View details
2025.05.16
【News】Bao Pharma's Recombinant Human Hyaluronidase Successfully Registered in the U.S. FDA DMF
View details
2025.04.29
【News】 Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives NMPA Approval for New Indication Clinical Trial
View details
2025.04.21
World's First Low-Immunogenic IgG-Degrading Enzyme — Ricefidase Phase III Clinical Trial Officially Launched
View details
1
2
3